ArticleCureus2024
Successful Treatment of Refractory Asthma Clinically Diagnosed As Eosinophilic Granulomatosis With Polyangiitis in a Hairdresser Using Tezepelumab.
Article in Cureus, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
We report a case of a 53-year-old male hairdresser with refractory asthma clinically diagnosed as eosinophilic granulomatosis with polyangiitis (EGPA) who showed remarkable improvement with tezepelumab after failing mepolizumab therapy. The patient presented with a three-year history of progressive multisystem involvement, including anosmia, asthma, hearing loss, and skin rash. The patient was clinically diagnosed as EGPA based on asthma, sinusitis with nasal polyps, eosinophilia, and purpura. Despite initial improvement with oral corticosteroids and mepolizumab, he experienced recurrent exacerbations of asthma. Tezepelumab was initiated, resulting in significant symptom improvement, successful corticosteroid tapering, and marked enhancement in pulmonary function tests. This case suggests that tezepelumab may be an effective treatment option for patients with refractory asthma, particularly those with suspected occupational exposure. Further research is needed to identify factors that predict response to different biologic therapies in refractory EGPA-related asthma and to explore the potential role of occupational exposures in treatment outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.